Medivive partners with leaders in drug development, clinical education, and pharmaceutical quality to bring the best NAD+ product to US physicians and their patients.
NAD+ is one of the most powerful and fastest-growing therapeutics in clinical practice today. Demand has outpaced quality. The compounded NAD+ market is flooded with low-quality products, and patients are too often using unsafe formulations that put them at risk.
Medivive was built to fix that. We assembled a coalition of specialists, each a recognized leader in their field, to deliver a high-quality NAD+ injector pen that is safe to use, easy for patients to adhere to, and easy for physicians to prescribe. Medivive is the tech platform that brings the coalition together into a single, frictionless prescribing experience.
No single company could have built this product alone. Medivive's role was to find the right partner for each part of the value chain and unify them into one workflow.
UK-based developer behind the original NAD+ formulation. Holder of a Medical Specials license, a rare UK regulatory designation requiring rigorous manufacturing and testing standards.
FDA-registered cGMP 503B outsourcing facility in San Diego. Received the formulation from SpectrumX through a formal technology transfer and now manufactures it to the same standard.
Licensed 503A pharmacy with PCAB accreditation and LegitScript certification. Dispenses every prescription cold-chain, direct to patients across 41 states.
Founded by Dr. William Seeds, MD, the SSRP Institute is a leading clinical education organization for cellular medicine. Medivive is a Trusted Partner of the Institute.
SpectrumX, based in the United Kingdom, invested in a full drug development program to create an NAD+ formulation with exceptional stability, potency, and purity. The program produced a prefilled subcutaneous injector pen delivering 1,000 mg of NAD+ as a 30-day supply with adjustable dosing (1 unit = 3.33 mg NAD+).
SpectrumX holds a Medical Specials license, a UK regulatory designation that requires rigorous manufacturing quality, testing, and documentation standards.
That is the standard the Medivive NAD+ pen was developed to. When the formulation was transferred to VeV Scientific in San Diego, it carried that quality bar with it.
The coalition is the foundation. Medivive is the layer that brings it together for physicians. We built a prescribing platform that handles credentialing, patient entry, prescription submission, and refill continuity in one workflow, so physicians can prescribe in under two minutes and Chemistry Rx can dispense and fulfill each patient-specific prescription without anything touching your practice.
This is what makes the Medivive NAD+ pen different from any other compounded NAD+ product on the market: drug-development origin, cGMP manufacturing, licensed pharmacy dispensing, clinical education backing, and a single technology platform that makes all of it work as one product for the prescriber.
The Medivive supply chain operates within the DQSA and Section 503B framework. The arrangement supports compliant distribution from a 503B outsourcing facility to a state-licensed pharmacy for patient-specific dispensing. A formal legal opinion letter from outside counsel is available to physicians upon request.
Contact us at clyde@medivive.com or schedule a call.